On Monday, the companies Pfizer Inc. and BioNTech said their COVID-19 vaccine has a robust immune response in children aged 5-11. They plan to submit results to regulators “with urgency” as they want authorization of the age group in the United States, Europe, and elsewhere. The companies explained that the immune response in the five to eleven-year-olds in their Phase II/III clinical trial matched the older age groups.
Alberta Bourla, Pfizer’s chief executive said “Since July, pediatric cases of COVID-19 have risen by 240 per cent in the U.S., underscoring the public health need for vaccinations,” She further explained that “These trials results provide a strong foundation for seeking authorization of our vaccine for children five to 11 years old, and we plan to submit them to the FDA and other regulators with urgency.”
As schools in the U.S. are already open nationwide, a quicker authorization of this vaccine could help mitigate a surge of cases in the fall. The vaccine, called Comirnaty, has been authorized for children as young as 12 in many countries, It was originally only for people 16-years-and-older in December 2020.
For more information about the source click HERE